Nate Wilson

Melanoma medical oncologist @WinshipAtEmory | via @UMHemOncFellows @UTHimres @rushumedcollege @KnoxCollege1837 |

[Nate Wilson @Nate_WilsonMD]

I’ve been bad at keeping up with posting during fellowship, but excited to announce that I will be starting my post-training career as a melanoma medical oncologist @WinshipAtEmory next week. So grateful for my mentors, support system, and very excited for this next chapter!

[The Fellow On Call @TheFellowOnCall]

🚨Hot off the press: A simultaneous publication in @JCOOP_ASCO alongside @vpatelmd’s presentation highlighting the 1st cluster randomized study evaluating podcasts for heme/onc education!

The outcome: @TheFellowOnCall and @TwoOncDocs should be included for h/o fellow education!

[UM Hematology/Oncology Fellowship @UMHemOncFellows]

Always a great time at UM ASCO reception!

[Mohammad Jad Moussa, MD, MSc @mjmoussa_]

BRIDGING GU ONCOLOGY & INTERNAL MEDICINE - @OAlhalabiMD #NupurKikaniMD @MDAndersonNews

Led with star colleague @Nate_WilsonMD (Ex-Chief @UTHimres), we share an ORIGINAL report on mgt of systemic toxicity of an ADC that changed bladder cancer care 🔗https://t.co/DbXrUTQwF0👇1/

[Mohammad Jad Moussa, MD, MSc @mjmoussa_]

⚡️NOW in @jitcancer👉Nivo/ipi in metastatic variant histology renal cell carcinoma

👇Mentored by kidney cancer legend #NizarTannirMD & @OAlhalabiMD, happy to share our experience @MDAndersonNews co-led w/ terrific friends @Nate_WilsonMD & Jaanki!
🔗https://t.co/Cap44uJLr0🧵1/

[Tarek Haykal, MD, MHS @TarekHaykal1]

Congrats @Nate_WilsonMD on this well written piece!

Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer? - The American Journal of Surgery https://t.co/4nopq7G6JE
@UMHemOncFellows

[Mohammad Jad Moussa, MD, MSc @mjmoussa_]

🔥 OUR LATEST #OriginalResearch in @CancerMedicineJ on Small Cell Neuroendocrine Carcinoma of the Urinary Tract (SCNEC-URO)👉What drives post-surgical relapse in this aggressive disease? @OAlhalabiMD @DocMattCampbell @MDAndersonNews

🔗https://t.co/LPk89eqoJV A thread🧵1/

[Toni Choueiri, MD @DrChoueiri]

END OF YEAR TOP ALL CANCER TRIALS in 2024!

JUST in on 1 JAN 2025:

Paper 1:

#neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @A@ASCO @ProfCUBlankNKI

https://t.co/3ndFElEAA8

[Omar Alhalabi, MD @OAlhalabiMD]

Hot off the press. Excited to share work done by stellar @UroOnc fellow @AmandaMyersMD mentored by @UroDocAsh
Further advancing knowledge on aggressive #bladdercancer subtypes.
T1 nonmuscle invasive small cell neuroendocrine carcinoma
🔗 https://t.co/VGGuv8DKRx

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Thanks 🙏 🙏 🙏 to @umichmedicine Div HemOnc for hosting me for Grand Rounds visiting Professor talk and visit ! @Nate_WilsonMD @KMirza @acweyand @kristenpettitmd @Berninini
🙌 #BPDCN #MPNSM #RareDisease #leusm

[UM Hematology/Oncology Fellowship @UMHemOncFellows]

Strong UM Fellow representation at the annual MSHO conference!

[Mohammad Jad Moussa, MD, MSc @mjmoussa_]

👋This is Mohammad Jad, Postdoc. Fellow & Postdoc. Association Team Leader @MDAndersonNews, mentored by @DocMattCampbell & @OAlhalabiMD
👉Applying for #InternalMedicine Residency #Match2025

🙏Dreaming of becoming a humane #oncologist through purposeful science – excited to find the right #IM program to make this dream a reality!

AAMC ID: 15705243 #IMG

[Dr Joshua Walinjom @walinjom]

Dermatology: important diagnosis

[S Faiz @sfaiz212]

Great #MultiDisciplinary work led by #MDAPulmonary @sotofelipe26 @ajaysheshadri Lydia Glick
@BCM_InternalMed @Nate_WilsonMD @UTHimres @PalaskasN @MehmetAltanMD on #LungCancer #ICIs #ILAs @MDAndersonNews

https://t.co/zwgKRViPqu

[Anirban Maitra @Aiims1742]

The Cancer-Immunity Cycle
By Ira Mellman &amp; colleagues in @ImmunityCP
2013:
https://t.co/yCcVYLaHjY
2023 update:
https://t.co/LWighZZ0QL
(L) 2013 (R) 2023
The underlying concepts have been the capstone for a lot of modern day cancer immunotherapy research.

[Nate Wilson @Nate_WilsonMD]

Important work led by rising ⭐️ @sotofelipe26 and mentors @MehmetAltanMD @ajaysheshadri to better understand outcomes for patients with NSCLC who have developed ICI-related pneumonitis https://t.co/9fPEYLSMXj

[Nate Wilson @Nate_WilsonMD]

Very grateful for my experience attending the @AACR-@ASCO Methods in Clinical Cancer Research Workshop in La Jolla. Humbling to be surrounded by such incredible people, ideas, current and future leaders in this field

[OncoDaily @oncodaily]

DOR to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation
@drenriquegrande @mjmoussa_ @Nate_WilsonMD @VivekSubbiah @DocMattCampbell @PavlosMsaouel @OAlhalabiMD
https://t.co/MfPsWqTGJ1

#Cancer #BladderCancer #CancerResearch #OncoDaily #Oncology

[UM Hematology/Oncology Fellowship @UMHemOncFellows]

Amazing time at the lake house celebrating the arrival of our new first year fellows and beginning of the new academic year!

[Mohammad Jad Moussa, MD, MSc @mjmoussa_]

⚡️NOW IN PRESS: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy🧬 #PrecisionOncology

👉GU ASCO #GU24: Original multi-institutional series on off-label use of lurbi in SCBC-enriched GU cohorts @OAlhalabiMD @Parminder1699 @AlanBryce9
👉#ASCO24: Phase II LASER study announcement (lurbi +/- avelumab)🌟@SaadAtiq24 @apolo_andrea
👉Now: Our structured #report @CurrentOncology with a hypothesis-testing paradigm, awaiting objective response

🔗 https://t.co/WobylPjYY1